Workflow
Biora Therapeutics(BIOR)
icon
Search documents
Biora Therapeutics Successfully Completes Restructuring Process
Globenewswire· 2025-03-31 12:00
Core Viewpoint - Biora Therapeutics has successfully completed its court-supervised restructuring, emerging as a privately held company with a stronger balance sheet and new financing to support the development of its BioJet™ platform [1][2]. Group 1: Company Overview - Biora Therapeutics is a biotech company focused on developing the first swallowable autoinjector, aiming to revolutionize the delivery of biologic pharmaceuticals [3]. - The BioJet™ platform is designed to replace traditional injections with a needle-free, oral delivery method for macromolecules [3]. Group 2: Technology and Development - The BioJet technology autonomously delivers a variety of molecules, including proteins, peptides, and nucleic acids, with a capacity exceeding 300 microliters, allowing for doses greater than 50 milligrams [4]. - The company is positioned to accelerate the development of the BioJet platform, which can deliver industry-leading payloads in a commercially desirable format [2]. Group 3: Financial and Ownership Changes - Following the restructuring, ownership of Biora transitioned to certain lenders, including Davidson Kempner Capital Management LP, Context Capital Management LLC, and funds managed by Highbridge Capital Management LLC, with existing common shares being cancelled [2].
Biora Therapeutics Undertakes Chapter 11 Sale Process to Position Business for Future Growth
Newsfilter· 2024-12-30 13:00
Sale process will help enable next stage of product development Secures up to $10.25 million in new financing to support ongoing business operations SAN DIEGO, Dec. 30, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. ("Biora" or the "Company"), a biotech company developing smart pill-based therapeutic platforms, today announced it has reached an agreement with certain of its prepetition creditors (the "Lenders") to provide financing to support a chapter 11 sale process, which will ultimately lead to a str ...
Biora Therapeutics(BIOR) - 2024 Q3 - Quarterly Report
2024-11-14 21:10
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 per share BIOR The Nasdaq Global Market ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHAN ...
Biora Therapeutics(BIOR) - 2024 Q3 - Quarterly Results
2024-11-14 21:05
Exhibit 99.1 Biora Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results Testing in advanced animal model planned in Q4 for smaller, 00-size BioJet device with largest capacity of any ingestible injectable Company granted extension until December 9 to regain compliance with Nasdaq listing requirements for market value of securities SAN DIEGO, November 14, 2024 – Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company reimagining therapeutic delivery, today provided a c ...
Biora Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results
GlobeNewswire News Room· 2024-11-14 13:00
Testing in advanced animal model planned in Q4 for smaller, 00-size BioJet device with largest capacity of any ingestible injectable Company granted extension until December 9 to regain compliance with Nasdaq listing requirements for market value of securities SAN DIEGO, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company reimagining therapeutic delivery, today provided a corporate update and reported financial results for the third quarter ended September 30, 202 ...
Biora Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate Update
GlobeNewswire News Room· 2024-11-07 21:30
SAN DIEGO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company reimagining therapeutic delivery, today announced it will report financial results and provide a corporate update for the third quarter ended September 30, 2024. Company management will host a webcast and conference call on Thursday, November 14, 2024, after the close of financial markets. Conference Call and Webcast InformationDate: Thursday, November 14, 2024Time: 4:30 PM Eastern time / 1:30 PM Pacifi ...
Biora Therapeutics(BIOR) - 2024 Q2 - Earnings Call Transcript
2024-08-12 23:54
Biora Therapeutics, Inc. (NASDAQ:BIOR) Q2 2024 Earnings Conference Call August 12, 2024 4:30 PM ET Company Participants Chuck Padala - Managing Director, LifeSci Advisors Adi Mohanty - Chief Executive Officer Eric d'Esparbes - Chief Financial Officer Conference Call Participants John Vandermosten - Zacks Small-Cap Research Joseph Pantginis - H.C. Wainwright Operator Welcome to the Biora Therapeutics Second Quarter 2024 Financial Results Call. At this time, all participants are in a listen-only mode. A brief ...
Biora Therapeutics(BIOR) - 2024 Q2 - Quarterly Report
2024-08-12 20:30
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 per share BIOR The Nasdaq Global Market Large accelerated filer ☐ Accelerated filer ☐ Non-accelerated filer ☒ Smaller reporting company ☒ Emerging growth company ☒ FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPO ...
Biora Therapeutics(BIOR) - 2024 Q2 - Quarterly Results
2024-08-12 20:15
Exhibit 99.1 Biora Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results Phase 1 clinical trial results for BT-600 demonstrate precise drug delivery to the colon with low systemic exposure, supporting clinical development plan Company secures up to $16M funding from existing investors supported by BT-600 results and progress toward BioJet TM partnership Management will host conference call and webcast today at 4:30 PM Eastern / 1:30 PM Pacific SAN DIEGO, August 12, 2024 – ...
Biora Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results
GlobeNewswire News Room· 2024-08-12 20:15
Core Insights - Biora Therapeutics has successfully completed a Phase 1 clinical trial for BT-600, demonstrating effective drug delivery to the colon with minimal systemic exposure, which supports its clinical development plan [1][2][3] - The company has secured up to $16 million in funding from existing investors, reflecting confidence in its progress and the results from the BT-600 trial [1][4] - Management is actively pursuing partnerships for its BioJet™ platform, with discussions ongoing with multiple large pharmaceutical companies [2][5] Clinical Development - The Phase 1 trial for BT-600 met all study objectives, showing a pharmacokinetic profile that supports localized drug delivery to the colon [3] - The trial results indicated that systemic drug exposure was three to four times lower than conventional oral tofacitinib, suggesting a significant advantage in reducing potential side effects [3] - The NaviCap devices used in the trial were well tolerated, with no serious adverse events reported [3] Financial Performance - For Q2 2024, Biora reported operating expenses of $16.1 million, consistent with the previous quarter, and a net income of $6.5 million, a significant improvement compared to a net loss of $4.2 million in Q1 2024 [6][7] - Year-over-year, operating expenses increased from $14.9 million in Q2 2023 to $16.1 million in Q2 2024, while net income improved from a loss of $17.8 million in Q2 2023 to a gain of $6.5 million in Q2 2024 [8][9] Future Milestones - Biora plans to present Phase 1 clinical trial data for BT-600 at the American College of Gastroenterology annual meeting in October 2024 [5] - The initiation of a Phase 1B clinical study in active ulcerative colitis patients is anticipated toward the end of 2024 [5] - The company expects to finalize at least one partnership agreement for the BioJet platform in the near term, with additional agreements anticipated later in 2024 [5]